Sign in
Not yet recruitingPhase 4

Remimazolam versus propofol anesthesia and thinking problems after aortic arch surgery

Compares remimazolam and propofol anesthesia for memory and thinking changes after aortic arch surgery.

Key facts

Who runs it
Seoul National University Hospital
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Effects of Remimazolam on Postoperative Cognitive Dysfunction and Neuroinflammatory Biomarkers in Patients Undergoing Aortic Arch Surgery
Status
Not yet recruiting
Phase
Phase 4
People taking part
80 people, planned
Started
1 Nov 2026
Expected to end
30 Dec 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Remimazolam Besylate
  • propofol
Record updated
29 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who are scheduled for surgery to replace all or part of the aortic arch, the curved top part of the main artery. It compares two anaesthesia drugs, remimazolam and propofol, and their effects on memory and thinking after surgery.

Age
19 years or older
Sex
All sexes
Disease stage
Aortic arch disease needing total or partial aortic arch replacement. The surgery plans to stop blood flow or use special blood flow to the brain to protect it. Emergency surgery cannot join.
Earlier treatment
People who take opioids or benzodiazepines over a long time cannot join.

Main reasons for not taking part

  • Existing problems with memory or thinking (MMSE score <24)
  • Bleeding in the brain or stroke in the previous 3 months
  • Allergy to remimazolam or other benzodiazepines, or past alcohol or drug abuse
  • Severe liver disease (Child-Pugh class C) or kidney failure needing dialysis
  • Emergency surgery or acute aortic dissection (a sudden tear in the main artery wall)

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Adults aged 19 years or older
  • Patients scheduled to undergo total or partial aortic arch replacement for aortic arch disease, with planned circulatory arrest and/or selective cerebral perfusion as a cerebral protection strategy during surgery

Who cannot take part

  • Acute cerebral hemorrhage or cerebral infarction within the previous 3 months
  • Pre-existing cognitive impairment, defined as Mini-Mental State Examination (MMSE) score <24
  • History of hypersensitivity to remimazolam or other benzodiazepines
  • History of alcohol or substance abuse
  • Severe hepatic impairment (Child-Pugh class C)
  • Acute or chronic renal failure requiring dialysis Emergency surgery or acute aortic dissection
  • Chronic use of opioids or benzodiazepines

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to compare remimazolam- and propofol-based anesthesia for their effects on postoperative cognitive dysfunction in patients undergoing aortic arch surgery. These procedures involve a substantial risk of cerebral ischemia and reperfusion injury, which may contribute to postoperative cognitive decline. Although experimental studies have suggested potential neuroprotective effects of remimazolam, clinical evidence in patients undergoing high-risk aortic arch surgery remains limited. This prospective, randomized controlled trial will compare the incidence of postoperative cognitive dysfunction between patients receiving remimazolam- or propofol-based anesthesia. In addition, changes in circulating neuroinflammatory and neuronal injury biomarkers will be evaluated to explore the potential mechanisms underlying any neuroprotective effect of remimazolam. The findings may provide clinical evidence to guide anesthetic selection and improve neurological outcomes in patients undergoing aortic arch surgery.

The 2 groups in the trial

  • Remimazolam groupTreatment being tested

    Remimazolam Besylate (2mg/mL)

    Treatment: Remimazolam Besylate

  • Propofol groupTreatment being tested

    Propofol (20mg/mL)

    Treatment: propofol

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Remimazolam on Postoperative Cognitive Dysfunction and Neuroinflammatory Biomarkers in Patients Undergoing Aortic Arch Surgery: A Randomized Controlled Trial
Plain-language title
Remimazolam versus propofol anesthesia and thinking problems after aortic arch surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
29 October 2026